136 related articles for article (PubMed ID: 28042794)
41. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
42. Intraprostatic ethanol injection as an alternative therapy in patients with benign prostatic hyperplasia.
Espinoza AR
Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):158-164. PubMed ID: 30509604
[TBL] [Abstract][Full Text] [Related]
43. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
[TBL] [Abstract][Full Text] [Related]
44. Intraprostatic injections for lower urinary tract symptoms treatment.
Andersson KE
Curr Opin Urol; 2015 Jan; 25(1):12-8. PubMed ID: 25333915
[TBL] [Abstract][Full Text] [Related]
45. The application of botulinum toxin in the prostate.
Chuang YC; Chancellor MB
J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
[TBL] [Abstract][Full Text] [Related]
46. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
[TBL] [Abstract][Full Text] [Related]
47. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
48. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates.
Chuang YC; Chiang PH; Huang CC; Yoshimura N; Chancellor MB
Urology; 2005 Oct; 66(4):775-9. PubMed ID: 16230137
[TBL] [Abstract][Full Text] [Related]
49. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
50. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.
Arnouk R; Suzuki Bellucci CH; Benatuil Stull R; de Bessa J; Malave CA; Mendes Gomes C
ScientificWorldJournal; 2012; 2012():463574. PubMed ID: 22997495
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
52. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
Wein AJ
J Urol; 2005 Nov; 174(5):1903. PubMed ID: 16217335
[No Abstract] [Full Text] [Related]
53. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results.
Pisco J; Campos Pinheiro L; Bilhim T; Duarte M; Rio Tinto H; Fernandes L; Vaz Santos V; Oliveira AG
Radiology; 2013 Feb; 266(2):668-77. PubMed ID: 23204546
[TBL] [Abstract][Full Text] [Related]
54. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia.
Plante MK; Marks LS; Anderson R; Amling C; Rukstalis D; Badlani G; Getlin L; Vang E
J Urol; 2007 Mar; 177(3):1030-5; discussion 1035. PubMed ID: 17296405
[TBL] [Abstract][Full Text] [Related]
55. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs.
Chuang YC; Tu CH; Huang CC; Lin HJ; Chiang PH; Yoshimura N; Chancellor MB
BMC Urol; 2006 Apr; 6():12. PubMed ID: 16620393
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia.
Kellner DS; Armenakas NA; Brodherson M; Heyman J; Fracchia JA
Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705
[TBL] [Abstract][Full Text] [Related]
57. [Effects of intraprostatic injection of botulinum toxin A (BTX-A) on benign prostate hyperplasia].
Xu YP; Yu X; Ye ZQ; Pan TJ; Wen HD; Wang T
Zhonghua Nan Ke Xue; 2010 Oct; 16(10):905-10. PubMed ID: 21243754
[TBL] [Abstract][Full Text] [Related]
58. Injectables in the prostate.
Saemi AM; Plante MK
Curr Opin Urol; 2008 Jan; 18(1):28-33. PubMed ID: 18090486
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
60. [Botulinum toxin in the treatment of benign prostatic hyperplasia : an overview].
Boy S; Seif C; Braun PM; Jünemann KP
Urologe A; 2008 Nov; 47(11):1465-71. PubMed ID: 18685825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
